Massimo Cristofanilli, MD, director, Breast Care Center, Jefferson University Hospitals, discusses molecular subtyping in the diagnosis and treatment of breast can
Clinical Pearls
Massimo Cristofanilli, MD, director, Breast Care Center, Jefferson University Hospitals, discusses molecular subtyping in the diagnosis and treatment of breast cancer.
ASCO and CAP are trying to better define patients who may benefit from treatment with targeted therapies
The current method of detecting HER2 overexpression/amplification may miss a portion of patients; molecular subtyping is a more accurate way to identify these patients
A different molecular profiling signature should be offered to patients who are defined by current guidelines as 'borderline'
